| Name | Tirzepatide | CAS# | 2023788-19-2 | |
|---|---|---|---|---|
| Price | ¥2600.0/1g | Purity | 99.8% | |
| Stocking Period |
3 Day | Stock | Inquiry |
| Detail
Product Information
Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes. Tirzepatide (LY3298176) shows significantly better efficacy with regard to glucose control and weight loss than do Dulaglutide[1]. Related Catalog Research Areas >> Metabolic Disease Signaling Pathways >> GPCR/G Protein >> Glucagon Receptor References [1]. Frias JP, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018 Nov 17;392(10160):2180-2193. [2]. Frias JP, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018 Nov 17;392(10160):2180-2193. Chemical & Physical Properties Molecular Formula C225H348N48O68 Molecular Weight 4813.45 Storage condition 2-8℃ |